Current evidence and major treatment guidelines support staying on buprenorphine as long as it is helping — for many people, indefinitely, the way any chronic illness is managed. Studies show mortality and overdose risk climb sharply after stopping, no matter how long someone was in treatment first. No provider should ever push you to taper; if stopping ever happens, it is your decision, made slowly and safely.

It’s one of the first questions almost every new patient asks — and one where the medical consensus has genuinely shifted. The honest, evidence-based answer: as long as it’s helping, and there is no expiration date.

What do the major treatment guidelines say?

Opioid use disorder (OUD) is a chronic illness, and the medication is treated accordingly. The American Society of Addiction Medicine’s National Practice Guideline states there is no recommended time limit for buprenorphine treatment. SAMHSA’s TIP 63 says patients can continue the medication indefinitely — for as long as it benefits them. And the Rutgers Medication-Assisted Treatment Center of Excellence puts it plainly: evidence strongly suggests the medication be continued indefinitely, unless the patient adamantly wants to stop or the treatment itself is causing harm — and providers should never be the ones deciding when a patient stops.

This shift shows up in the language itself. The field has moved away from “medication-assisted treatment” (MAT) toward “medication for opioid use disorder” (MOUD) — because the medication isn’t assisting some other, realer treatment. For a chronic illness like OUD, the medication is the treatment, the way insulin is for diabetes and antiretrovirals are for HIV.

What does the evidence show about staying on versus stopping?

The data behind the guidelines is consistent and sobering:

A BMJ meta-analysis by Sordo and colleagues (2017), pooling cohorts of over 138,000 patients, found all-cause mortality among people out of buprenorphine treatment was more than double the rate of those in treatment.
In a landmark study of overdose survivors, Larochelle and colleagues (Annals of Internal Medicine, 2018) found buprenorphine was associated with a 38% reduction in opioid-related deaths over the following year.
Williams and colleagues (American Journal of Psychiatry, 2020) found that the longer patients stayed on buprenorphine, the less likely they were to visit the ER, be hospitalized, or fill an opioid prescription — but whether they stopped after 6, 12, or 18 months, every group faced a similar overdose risk (over 5%) after discontinuing. More time on the medication doesn’t make stopping safe; being on the medication is what’s protective.

“Isn’t this just trading one addiction for another?”

No — and the distinction matters. Addiction is compulsive use despite harm: escalating doses, cravings, life organized around the drug. What patients on stable Suboxone® doses have is physical dependence — the same thing people have with blood-pressure medication or antidepressants. The dose doesn’t climb, there’s no high, and life reorganizes around work and family instead of the next dose. Nobody asks a person with diabetes when they plan to get off insulin.

This myth keeps people from starting treatment and pressures others into quitting too soon. If family members are the source of that pressure, bring them to a visit — we’re glad to walk them through the evidence. Our page on how Suboxone works is a good starting point too.

What actually happens when people taper?

The taper-versus-maintenance question has been studied directly, and the results all point the same way:

In a randomized trial by Kakko and colleagues (Lancet, 2003), patients tapered off buprenorphine did catastrophically worse than those maintained on it: every patient in the taper group relapsed, and four of them died — versus roughly 75% retention and zero deaths in the maintenance group.
A primary-care trial by Fiellin and colleagues (JAMA Internal Medicine, 2014) found tapered patients used more illicit opioids and sustained less abstinence than patients kept on maintenance.
An analysis of real-world taper attempts by Graves and colleagues (Journal of Addiction Medicine, 2021) estimated that only about 15% of people who set out to taper off succeed — and among those who did, the final stretch from 2mg to zero took a median of 93 days.

And in the fentanyl era, the stakes of a post-taper relapse are higher than they’ve ever been, because tolerance falls quickly once the medication stops.

So who decides if I ever stop?

You do. Full stop. Per current guidance, providers should never advise or dictate when a patient stops or tapers buprenorphine — not us, and not a counselor, judge, employer, or family member either. At RecoverWell there is no program clock, no expected end date, and no pressure to “graduate.” Staying on a stable dose long-term isn’t a failure to finish treatment; for most patients it is the treatment succeeding.

What if I still want to stop someday?

Then we support you — safely, and honestly about the risks. There is no proven protocol for tapering off buprenorphine, but the limited evidence favors going very slowly, in tiny steps, holding wherever you’re comfortable, with the option to pause or reverse at any point without shame. Long-acting options can also reduce risk along the way. What we won’t do is rush it, set a deadline, or let anyone else set one for you — and if a taper stops feeling right, going back to your stable dose is a course correction, not a relapse.

The bottom line

The goal of treatment was never to get off Suboxone® as fast as possible — it’s to keep you alive and give you your life back. The evidence says the medication does that best when you stay on it. However long that turns out to be, we’ll be here the whole way.

Sources

This article is for general education and isn't medical advice. For guidance about your own care, talk with your provider.

How Long Will I Be on Suboxone?